JUBILANT LIFE SCIENCES LIMITED - 530019 - Issuance Of Commercial Papers Of Rs. 90 Crore
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company has issued Commercial Papers ('CPs') of Rs. 90 Crore on November 26, 2020. JUBILANT LIFE SCIENCES LIMITED - 530019 - Compliance Under Regulation 23(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015
In terms of Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose disclosure of Related Party Transactions on a consolidated basis, in the format specified in the accounting standards for the half year ended September 30, 2020.
Accumulate Jubilant Life Sciences; target of Rs 752: Prabhudas Lilladher
Prabhudas Lilladher recommended accumulate rating on Jubilant Life Sciences with a target price of Rs 752 in its research report dated November 05, 2020. JUBILANT LIFE SCIENCES LIMITED - 530019 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the management of the Company shall be attending the Centrum Broking's Annual Investor Conclave through virtual mode from November 11-12 and 16-17, 2020. The schedule may undergo change due to exigencies on the part of Investor/ Analysts/ Company. We also enclose the presentation to be used during the meetings.
Buy Jubilant Life Sciences; target of Rs 855: Motilal Oswal
Motilal Oswal is bullish on Jubilant Life Sciences recommended buy rating on the stock with a target price of Rs 855 in its research report dated November 04, 2020. JUBILANT LIFE SCIENCES LIMITED - 530019 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificates under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Buy Jubilant Life Sciences; target of Rs 850: ICICI Direct
ICICI Direct is bullish on Jubilant Life Sciences recommended buy rating on the stock with a target price of Rs 850 in its research report dated November 08, 2020.
Jubilant Life Sciences Q2 net profit declines 10% to Rs 224 crore
The company had posted a net profit of Rs 249.39 crore for the corresponding period of the previous fiscal, Jubilant Life Sciences said in a BSE filing. JUBILANT LIFE SCIENCES LIMITED - 530019 - Copy of Newspaper Publication
Jubilant Life Sciences Ltd has submitted to BSE a copy of "Newspaper Publication". JUBILANT LIFE SCIENCES LIMITED - 530019 - Compliance With Regulation 52(5) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
We enclose a certificate dated November 4, 2020 received from Axis Trustee Services Limited, Debenture Trustee, pursuant to Regulation 52 (5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the Non-Convertible Debentures of the Company listed on National Stock Exchange of India Limited.